Does Fampridine improve fatigue in patients with Multiple Sclerosis.

Phase 2

Completed

• Conditions: Multiple Sclerosis.; Neurological - Multiple sclerosis; Inflammatory and Immune System - Autoimmune diseases

• Registration Number: ACTRN12611000799954
• Lead Sponsor: niveristy of New South Wales

Brief Summary

Fampridine treatment improved walking distance.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-29
• Study Completion: 2013-10-31
• Last Update Posted: 16 March 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Definitive diagnosis of MS
18-80 years of age.
Able to provide informed consent.

Exclusion Criteria

History of seizures.
Current treatment with anticonvulsant medication.
Pregnancy or lactation. Contraception is required in pre-menopausal female patients.
History of moderate-severe renal impairment.
Presence of serious psychiatric disorder (e.g major depression, bipolar disorder)
Enrolled in another clinical trial involving an investigational agent.
Known allergy to pyridine-containing substances.
History of renal dysfunction, with eGFR <60 ml.
history of acute relapse within last 60 days
EDSS score >6.0

Study & Design

• Study Type: Interventional
• Study Design: Not specified